Institutional Corruption and the Pharmaceutical Policy

Journal of Law, Medicine and Ethics 41 (3):544-552 (2013)
  Copy   BIBTEX

Abstract

Today, the goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption — that is, widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. In this symposium, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and what is corrupted. We will see that the pharmaceutical industry's own purposes are often undermined. Furthermore, pharmaceutical industry funding of election campaigns and lobbying skews the legislative process that sets pharmaceutical policy. Moreover, certain practices have corrupted medical research, the production of medical knowledge, the practice of medicine, drug safety, the Food and Drug Administration's oversight of the pharmaceutical market, and the trustworthiness of patient advocacy organizations

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 101,337

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Five Un-Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
Ethics and the Business of Biomedicine.Denis Gordon Arnold (ed.) - 2009 - New York: Cambridge University Press.
The Purchased Patient Advocate.Carl Elliott - 2018 - Hastings Center Report 48 (2):40-41.

Analytics

Added to PP
2013-10-02

Downloads
74 (#283,290)

6 months
6 (#858,075)

Historical graph of downloads
How can I increase my downloads?